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INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) – the most prevalent 
chronic liver disorder – is an increasing and serious worldwide 
health concern. It is considered the hepatic expression of  meta-
bolic syndrome and defined by excessive hepatic fat content in the 
absence of excessive alcohol consumption. NAFLD encompasses 
a broad range of histological changes varying from simple stea-
tosis to non-alcoholic steatohepatitis (NASH) with potential for 
progression to cirrhosis and hepatocellular carcinoma. Owing to 
the very high global prevalence of NAFLD, twenty-five percent, 
it is of paramount importance to understand its pathogenesis(1).
Notwithstanding efforts, the etiology of NAFLD and the rea-
sons for its progression to NASH has not been fully comprehended 
yet. Nevertheless, it is well established that NAFLD is strongly 
connected with metabolic disorders such as abnormal glucose 
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tolerance(2), insulin resistance (IR)(3,4), type 2 diabetes (T2D)(5), and 
obesity(6). So, IR is one of the underlying causes of NAFLD. The 
severity of histological progression of NAFLD is closely related 
to insulin sensitivity independent of body mass index (BMI)(7), as 
well as NASH patients compared with the patients with simple fatty 
liver have more severe IR(8). Additionally, NAFLD patients with 
IR in comparison to those without IR show much higher rates of 
elevated liver enzymes of aspartate aminotransferase and alanine 
aminotransferase(9). Furthermore, NAFLD patients have a higher 
circulating level of insulin than controls(10). And finally, significant 
associations between insulin (INS) and insulin receptor (INSR) 
gene polymorphisms and circulating insulin levels(11,12), IR(13,14), 
BMI(15) and risk of T2D(16,17) have been reported.
Therefore, these observations led us to investigate whether 
insulin resistance-related genes (INS and INSR) were associated 
with NAFLD risk in Iranian population. 
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METHODS
Participants
The study population consisted of  159 controls (age range, 
33–82 years) and 153 cases with biopsy-proven NAFLD (age 
range, 32–88 years). This hospital based case-control study was a 
multicenter research and the centers are as follows: (1) Research 
Institute for Gastroenterology and Liver Diseases, Shahid Beheshti 
University of  Medical Sciences (2) Gastrointestinal and Liver 
Diseases Research Center, Guilan University of Medical Sciences 
(3) Internal Medicine Department, Semnan University of Medical 
Sciences (4) Colorectal Research Center, Iran University of Medical 
Sciences (5) Faculty of Science, University of Mohaghegh Arda-
bili (6) School of Medicine, Qom University of Medical Sciences 
(7) Gut and Liver Research Center, Mazandaran University of 
Medical Sciences. All the participants were Iranian and genetically 
unrelated. They were informed about the aims of the study and 
their demographic, anthropometric, and clinical information was 
collected by self-administered questionnaires and before diagnosis 
of  NAFLD. NAFLD diagnosis was established in accordance 
with the following criteria: (1) ultrasonographic evidence of fatty 
liver and high serum levels of liver enzymes (ALT, AST, GGT) (2) 
alcohol consumption <20 g/day in men and <10 g/day in women 
(3) excluding patients with other causes of liver disease including 
viral hepatitis, Wilson’s disease, alpha-1 antitrypsin deficiency, and 
use of drugs known to induce steatosis (4) histologic confirmation 
of NAFLD by an experienced pathologist who was unaware of the 
patients’ clinical and biochemical data and scored biopsies using the 
Brunt’s criteria. Steatosis and necroinflammation were graded from 0 
to 3 and fibrosis was staged from 0 to 4(18). The controls had no liver 
steatosis (examined by abdominal ultrasonography), neither elevated 
liver enzymes and viral hepatitis infection (examined by blood test). 
None of them were alcoholics, drank regularly nor were on regular 
medications. The controls subjects were recruited from the institute 
staff and medical students. The Ethical Committee of the Institute 
reviewed and approved this study which was conducted according to 
the principles of the Helsinki Declaration. BMI of each subject was 
calculated by the standard formula: weight kg/height squared (m2).
Genotype analysis
Five milliliters of peripheral blood samples from each of the 
312 subjects were collected in tubes containing ethylene diami-
netetraacetic acid (EDTA) as an anticoagulant and store at 4ºC. 
In this study, genomic DNA was purified from peripheral blood 
leucocytes using standard methods. Using PCR-RFLP method all 
the four studied polymorphisms (INS rs3842752, INS rs689, INSR 
rs1052371, and INSR rs1799817) were genotyped. Our criteria 
for selecting these SNPs were their position in the gene (exon, 
promoter or regulatory regions), use in previous genetic studies, 
and relatively high minor allele frequency (MAF). Moreover, labo-
ratory personnel who carried out the genotyping were blinded to 
case or control status. TABLE 1 indicates the details of the PCR 
and RFLP conditions. The PCR products were digested with the 
appropriate restriction enzymes (Fermentas, Leon-Rot, Germany) 
and the digested products were run on 2.5% to 3.5% agarose gels 
and then stained with ethidium bromide for visualization under 
UV light. Genotyping of the subjects were denoted on the basis of 
the digestion patterns and the presence or absence of the respective 
restriction enzymes sites. To check for genotyping error rate, we 
repeated the genotyping analysis of  around 20% of the samples 
that were selected randomly.
Statistical methods
Chi-square (χ2) test or t-test were used to compare differ-
ences in demographic, anthropometric or clinical parameters 
between the cases with NAFLD and controls. We also calculated 
differences in the allele frequencies of  polymorphisms between 
the different groups using χ2 test. To examine the distribution of 
the genotype frequencies logistic regression analysis was used. 
Logistic regression was also computed for adjusting confounding 
factors such as age and BMI. For all the alleles and genotypes, 
the odds ratios (OR) which present the measure of  associations 
were given with the respective 95% confidence intervals (95% 
CI). Statistical analyses were performed with SPSS software for 
Windows, version 25.0 (SPSS Inc. Chicago, IL, USA). In all sta-
tistical tests, a P<0.05 was considered to indicate a statistically 
significant difference.
TABLE 1. Insulin (INS) and insulin receptor (INSR) gene SNPs.









INS rs3842752 (C/T) 5’-TGTGGAACAATGCTGTACC-3’ 57 ºC 410 PstI C: 410
5’-GCTACTGAACAAGAAGTCAC-3’ T: 336+74
INS rs689 (T/A) 5’-TCCAGGACAGGCTGCATCAG-3’ 58 ºC 441 Alw26I A: 441
5’-AGCAATGGGCGGTTGGCTCA-3’ T: 230+211
INSR rs1052371 (T/C) 5’-CTAGTCAAGGTCCAGAACC-3’ 57 ºC 224 LweI T: 224
5’-AGGCACACAAAGGGACGAG-3’ C: 154+70
INSR rs1799817 (T/C) 5’-CCAAGGATGCTGTGTAGATAAG-3’ 60 ºC 317 Eco72I T: 317
5’-TCAGGAAAGCCAGCCCATGTC-3’ C: 274+43
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RESULTS
TABLE 2 presents demographic, anthropometric, clinical, and 
biochemical characteristics of the cases with NAFLD and the con-
trols. The cases were older (P<0.001), more likely to be overweight/
obese (P<0.001), males (P<0.001), and smokers (P=0.015) than 
the controls. Moreover, systolic blood pressure (SBP), diastolic 
blood pressure (DBP), as well as circulating levels of  aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), and 
gamma glutamyl transferase (GGT) were higher in the cases with 
NAFLD compared with the controls (P<0.001). 
The distribution of genotypes and alleles of INS rs3842752, 
INS rs689, INSR rs1052371, and INSR rs1799817 gene poly-
morphisms in cases with NAFLD and controls are provided in 
TABLE 3. The carriers of the INSR rs1799817 “TT” genotype com-
pared with the carriers of the “CC” genotype were associated with a 
decreased risk for NAFLD, and the difference remained significant 
even after adjustment for confounding factors including age, BMI, 
sex, smoking status, SBP, and DBP (P=0.018; OR=0.10, 95%CI 
=0.02–0.76). In other words, the INSR rs1799817 “TT” genotype 
had a 90% decreased risk for NAFLD. Nevertheless, as shown in 
TABLE 3, no statistically significant difference in genotype or al-
lele frequencies between the two groups of cases and controls was 
found for INS rs3842752, INS rs689, and INSR rs1052371 gene 
polymorphisms either before or after adjustment for confounding 
factors including age, BMI, sex, smoking status, SBP, and DBP.
TABLE 3. Distribution of insulin (INS) and insulin receptor (INSR) gene 
polymorphisms in cases with nonalcoholic fatty liver disease (NAFLD) 
and in controls*.
Gene (variant) Controls (n=159)
Cases 
(n=153)




   CC 124 (78.0) 107 (69.9) 1.0 (reference)
   CT 21 (13.2) 34 (22.2) 1.84 (0.41–8.33) 0.427
   TT 14 (8.8) 12 (7.9) 0.35 (0.04–3.22) 0.353
   CT and TT 35 (22.0) 46 (30.1) 1.07 (0.31–3.72) 0.910
   TT versus others 14 (8.8) 12 (7.9) 0.32 (0.04–2.94) 0.315
Allele-wise comparison
   C 269 (84.6) 248 (81.1) 1.0 (reference)
   T 49 (15.4) 58 (18.9) 1.28 (0.68–2.41) 0.449
INS (rs689)
Genotype-wise comparison
   AA 113 (71.1) 104 (68.0) 1.0 (reference)
   AT 37 (23.2) 44 (28.7) 1.85 (0.61–7.22) 0.793
   TT 9 (5.7) 5 (3.3) 0.68 (0.32–7.02) 0.513
   AT and TT 46 (28.9) 49 (32.0) 1.75 (0.88–5.43) 0.311
   TT versus others 9 (5.7) 5 (3.3) 0.59 (0.06–-3.76) 0.422
Allele-wise comparison
   A 263 (82.7) 252 (82.4) 1.0 (reference)
   T 55 (17.3) 54 (17.6) 1.08 (0.91–1.88) 0.877
INSR (rs1052371)
Genotype-wise comparison
   TT 110 (69.2) 94 (61.4) 1.0 (reference)
   TC 41 (25.8) 53 (34.6) 0.42 (0.05–3.84) 0.443
   CC 8 (5.0) 6 (4.0) 1.02 (0.30–3.43) 0.979
   TC and CC 49 (30.8) 59 (38.6) 0.86 (0.28–2.68) 0.797
   CC versus others 8 (5.0) 6 (4.0) 0.42 (0.05–3.66) 0.431
Allele-wise comparison
   T 261 (82.1) 241 (78.8) 1.0 (reference)
   C 57 (17.9) 65 (21.2) 1.23 (0.69–2.18) 0.484
INSR (rs1799817)
Genotype-wise comparison
   CC 107 (67.3) 105 (68.6) 1.0 (reference)
   CT 28 (17.6) 35 (22.9) 0.42 (0.21–1.52) 0.203
   TT 24 (15.1) 13 (8.5) 0.10 (0.02–0.76) 0.018
   CT and TT 52 (32.7) 48 (31.4) 0.84 (0.35–1.83) 0.417
   TT versus others 24 (15.1) 13 (8.5) 0.36 (0.13–1.29) 0.167
Allele-wise comparison
   C 242 (76.1) 245 (80.1) 1.0 (reference)
   T 76 (23.9) 61 (19.9) 0.89 (0.64–1.41) 0.520
* Variables presented as number (%). ** Adjusted for age, body mass index (BMI), sex, 
smoking status, systolic blood pressure (SBP), and diastolic blood pressure (DBP) in genotype-
-wise comparisons.







Age (years) 29.5(7.4) 38.3(9.2) <0.001
BMI(kg/m2) 23.7(3.1) 29.2(5.3) <0.001
Gender
    Men 83(52.2) 112(73.2)
    Women 76(47.8) 41(26.8) <0.001
Smoking status
    Never smoker 145(91.2) 114(74.5)
    Former smoker 9(5.7) 20(13.1)
    Current smoker 5(3.1) 19(12.4) 0.015
SBP (mmHg) 114.3(13.5) 123.7(15.2) <0.001
DBP (mmHg) 69.8(8.4) 74.7(9.6) <0.001
AST (IU/L) 19.8(7.4) 39.1(17.9) <0.001
ALT (IU/L) 19.6(10.5) 71.9(40.6) <0.001
GGT (IU/L) 18.7(8.8) 58.0(31.1) <0.001
Steatosis
    Grade 0 –
    Grade 1 40(26.1)
    Grade 2 82(53.6)
    Grade 3 31(20.3)
Necroinflammation
    Grade 0 47(30.7)
    Grade 1 59(38.6)
    Grade 2 45(29.4)
    Grade 3 2(1.3)
Fibrosis
    Stage 0 90(58.8)
    Stage 1 56(36.6)
    Stage 2 7(4.6)
    Stage 3 –
    Stage 4 –
* Variables presented as mean (SD) or number (%); BMI: Body mass index, SBP: systolic 
blood pressure, DBP: diastolic blood pressure, AST: aspartate aminotransferase, ALT: alanine 
aminotransferase, GGT: gamma glutamyl transferase.
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DISCUSSION
This case-control study was conducted to explore whether INS 
and INSR gene polymorphisms were associated with NAFLD 
risk. The “TT” genotype of INSR rs1799817 compared with “CC” 
genotype occurred more frequently in controls than cases with 
NAFLD and consequently “TT” genotype had a protective effect 
for NAFLD. Furthermore, this difference remained significant 
after adjustment for confounding factors including age, BMI, sex, 
smoking status, SBP, and DBP. Nevertheless, no significant dif-
ference was found for INSR rs1052371, INS rs3842752, and INS 
rs689 gene polymorphisms in either genotype or allele frequencies 
between the cases with NAFLD and the controls.
The underlying mechanisms of the pathogenesis of NAFLD 
still remain unclear, however, IR plays a pivotal role in the develop-
ment and progression of NAFLD. IR expedites the release of free 
fatty acid from adipose tissue and its influx into liver(3,4,19). Previous 
epidemiological reports have also revealed that HOMA-IR index is 
an independent predictor of the severity of liver fibrosis and the risk 
of disease progression increases in the patients with IR. It appears 
that insulin secretion increases in NAFLD patients to compensate 
for reduced insulin sensitivity to maintain glucose homeostasis in 
these patients(20,21). NAFLD has a significant genetic basis and its 
association with gene variants has been investigated over the past 
two decades. As insulin signaling pathway genes play crucial roles 
in glucose homeostasis, it is not surprising that they are potential 
candidate genes for metabolic disorders such as NAFLD and their 
dysregulation may lead to NAFLD(22).
The INSR gene, containing 22 exons, is located on short 
arm of  chromosome 19 and encodes INSR. INSR mediates the 
pleiotropic biological actions of  insulin through its potential abil-
ity for modulation of  the expression of  target genes. Therefore, 
any defects in INSR gene might impair the biological response 
to insulin and lead to IR. Previous studies demonstrated that 
liver-specific INSR knockout mice suffer from serious insulin 
resistance and glucose intolerance(23). And INSR gene mutations 
were detected in many patients with insulin resistance(24). Fur-
thermore, INSR gene polymorphisms are associated with plasma 
insulin concentration(12), IR(13,14), BMI(15) and risk of  T2D(16). In 
the present study, the associations between INSR rs1052371 and 
INSR rs1799817 polymorphisms and NAFLD susceptibility 
were investigated. No significant difference was observed for 
rs1052371 variant – located in the 3’ untranslated region (3’UTR) 
of  the INSR gene – between the cases with NAFLD and the 
controls. The 3’UTR region plays a key role in regulating gene 
expression and its mutations have been linked to some diseases 
including different cancers(25). Furthermore, the SNPs in UTRs 
of  the INSR gene are associated with insulin resistance(26). An-
other polymorphism studied here, rs1799817 located in exon 17 
of  the INSR gene, was associated with NAFLD risk; the “TT” 
genotype had a protective effect for NAFLD. The role of  exon 
17 in the function of  INSR gene and insulin signal transduction 
is vital due to the fact that it encodes the tyrosine kinase domain 
of  INSR protein(27). Mutations in the tyrosine kinase domain 
(exon 17–21) of  INSR gene cause severe hyperinsulinemia and 
insulin resistance(28). Nevertheless, the molecular mechanism 
through which rs1799817 variant may influence the function of 
INSR gene is still speculative and unknown. Rs1799817 does not 
change the amino acid sequence of  INSR protein (His1085His), 
although growing evidence indicates the likely effect of  this type 
of  SNPs in altering protein function(29). The other possible way 
is the rs1799817 effect on INSR mRNA level through the control 
of  mRNA splicing or mRNA stability. One hypothesis is that the 
rs1799817 “C” allele gives rise to a defect in the function of  INSR 
protein and, in turn, impairs the biological response to insulin 
and leads to insulin resistance and finally NAFLD. This theory 
is biologically plausible and in accordance with it, the “T” allele 
of  INSR rs1799817 polymorphism has a protective effect for 
T2D(16). More interestingly, recent evidence has also indicated 
that the “CC” genotype of rs1799817 significantly increases IR(14). 
Additionally, the frequency of  the ‘‘T’’ allele was higher in the 
controls compared with the insulin-resistant subjects(30) and the 
‘‘T’’ allele was more frequent in subjects with normal glucose tol-
erance than cases with type 2 diabetics, emphasizing the protective 
effect of ‘‘T’’ allele towards insulin resistance(31). These findings are 
in concordance with the above hypothesis and our finding. The 
other possible hypothesis linking INSR rs1799817 variant with 
NAFLD risk is through linkage disequilibrium. Rs1799817 may 
not be a functional polymorphism. Instead it might be in complete 
or partial linkage disequilibrium with an unidentified functional 
polymorphism of INSR gene. In support of  our hypothesis, it has 
also been demonstrated that the decrease of hepatic CEACAM1 – 
a transmembrane glycoprotein that undergoes phosphorylation by 
the insulin receptor tyrosine kinase and promotes the clearance of 
insulin from the blood largely in liver – causes insulin resistance, 
hyperinsulinemia, and hepatosteatosis and its overexpression 
curtails these metabolic abnormalities associated with NAFLD(32). 
And finally, gene polymorphisms that impair INSR signaling favor 
insulin resistance, obesity, and fibrosis development in NAFLD. 
The ectoenzyme nucleotide pyrophosphate phosphodiesterase 
1 (ENPP1) which interacts directly with INSR inhibits insulin 
signaling and when overexpressed causes insulin resistance. The 
121Gln allele of  ENPP1 Lys121Gln polymorphism is a gain-
of-function allele causing stronger interaction with INSR and 
inhibition of  its kinase activity(22,33). 
The other gene studied here, INS, is also involved in maintain-
ing glucose homeostasis. No significant association was detected 
between the INS rs3842752 variant – located in 3’UTR – and the 
INS rs689 polymorphism – located in promoter – and NAFLD 
susceptibility. Alterations in 3’UTR or promoter sequence may 
directly affect the function of protein. Alternatively, these varia-
tions per se might not be functional, instead they can be associ-
ated with epigenetic modifications that have functional effects on 
gene expression(34). Previous studies have reported elevated insulin 
concentrations in NAFLD patients than controls(10) as well as sig-
nificant associations between circulating insulin level and INS gene 
polymorphisms(11). Notwithstanding the biological plausibility, INS 
may not be a predisposing gene for NAFLD. Of course, in order to 
conclude that the gene does not play a role in the development and 
progression of NAFLD, other INS gene polymorphisms should 
be examined in other studies.
The present case-control study was well designed and we 
conducted multicenter collaborative research. We also used liver 
biopsy as the gold standard method for confirming the diagnosis 
of NAFLD. However, when interpreting our results, some potential 
limitations should be considered. One limitation was the mod-
est sample size that precluded doing detailed analyses. Another 
limitation was our lack of information on serum levels of insulin 
as well as HOMA-IR index. The other limitation was a potential 
information bias from the case-control study design.
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CONCLUSION
In summary, our findings reinforce the hypothesis that genetic 
polymorphisms related to insulin signaling pathway might play a 
role in NAFLD susceptibility. And interestingly, this observation 
is relevant from a theoretical viewpoint. Nonetheless, our results 
remain to be validated in additional investigations. 
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